Psychotropic drugs affect Ser9-phosphorylated GSK-3β protein levels in rodent frontal cortex

International Journal of Neuropsychopharmacology

Volumn 9, Issue 3, 2006, Pages 337-342

  Kozlovsky, Nitsan ^a   Amar, Shirly ^a   Belmaker, R H ^a   Agam, Galila ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b MENTAL HEALTH CENTER   (Israel)

Author keywords

Frontal cortex; Mood stabilizers; Neuroleptics; Phospho Ser9 glycogen synthase kinase 3

Indexed keywords

CITRIC ACID; CLOZAPINE; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; LITHIUM CHLORIDE; PSYCHOTROPIC AGENT; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; FRONTAL CORTEX; MOOD CHANGE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; FRONTAL LOBE; GLYCOGEN SYNTHASE KINASE 3; PHOSPHORYLATION; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; SERINE;

EID: 33646868139     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705006097     Document Type: Article

References (28)

1. Beasley C, Cotter D, Khan N, Pollard C, Sheppard P, Varndell I, Lovestone S, Anderton B, Everall I (2001). Glycogen synthase kinase-3beta immunoreactivity is reduced in the prefrontal cortex in schizophrenia. Neuroscience Letters 302, 117-120.
2. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG (2004). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proceedings of the National Academy of Sciences USA 101, 5099-5104.
3. Benedetti F, Bernasconi A, Lorenzi C, Pontiggia A, Serretti A, Colombo C, Smeraldi E (2004a). A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neuroscience Letters 355, 37-40.
4. Benedetti F, Serretti A, Colombo C, Lorenzi C, Tubazio V, Smeraldi E (2004b). A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Letters 368, 123-126.
5. Bersudsky Y, Patishi Y, Bitsch Jensen J, Mork A, Kofman O, Belmaker RH (1997). The effect of acute and chronic lithium on forskolin-induced reduction of rat activity. Journal of Neural Transmission 104, 943-952.
6. Brantjes H, Barker N, van Es J, Clevers H (2002). TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biological Chemistry 383, 255-261.
7. Chalecka-Franaszek E, Chuang DM (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proceedings of the National Academy of Sciences USA 96, 8745-8750.
8. Ciapparelli A, Dell'Osso L, Bandettini di Poggio A, Carmassi C, Cecconi D, Fenzi M, Chiavacci MC, Bottai M, Ramacciotti CE, Cassano GB (2003). Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. Journal of Clinical Psychiatry 64, 451-458.
9. Cohen P, Frame S (2001). The renaissance of GSK3. Nature Reviews Molecular Cell Biology 2, 769-776.
10. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789.
11. De Sarno P, Li X, Jope RS (2002). Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164.
12. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nature Genetics 36, 131-137.
13. Gould TD, Zarate CA, Manji HK (2004). Glycogen synthase kinase-3: a target for novel bipolar disorder treatments. Journal of Clinical Psychiatry 65, 10-21.
14. Jardemark KE, Liang X, Arvanov V, Wang RY (2000). Subchronic treatment with either clozapine, olanzapine or haloperidol produces a hyposensitive response of the rat cortical cells to N-methyl-D-aspartate. Neuroscience 100, 1-9.
15. Kaidanovich-Beilin O, Milman A, Weizman A, Pick CG, Eldar-Finkelman H (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biological Psychiatry 55, 781-784.
16. Kang UG, Seo MS, Roh MS, Kim Y, Yoon SC, Kim YS (2004). The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Letters 560, 115-119.
17. Kozlovsky N, Belmaker RH, Agam G (2000). Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients. American Journal of Psychiatry 157, 831-833.
18. Kozlovsky N, Nadri C, Belmaker RH, Agam G (2003). Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity. International Journal of Neuropsychopharmacology 6, 117-120.
19. Li X, Bijur GN, Jope RS (2002). Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disorder 4, 137-144.
20. Novak A, Dedhar S (1999). Signaling through beta-catenin and Lef/Tcf. Cellular and Molecular Life Sciences 56, 523-537.
21. Roh MS, Kang UG, Shin SY, Lee YH, Jung HY, Juhnn YS, Kim YS (2003). Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3beta after electroconvulsive shock in the rat brain. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 1-5.
22. Ruel L, Stambolic V, Ali A, Manoukian AS, Woodgett JR (1999). Regulation of the protein kinase activity of Shaggy (Zeste-white3) by components of the wingless pathway in Drosophila cells and embryos. Journal of Biological Chemistry 274, 21790-21796.
23. Shaldubina A, Einat H, Szechtman H, Shimon H, Belmaker RH (2002). Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. Journal of Neural Transmission 109, 433-440.
24. Shapiro J, Belmaker RH, Biegon A, Seker A, Agam G (2000). Scyllo-inositol in post-mortem brain of bipolar, unipolar and schizophrenic patients. Journal of Neural Transmission 107, 603-607.
25. Sharp FR, Tomitaka M, Bernaudin M, Tomitaka S (2001). Psychosis: pathological activation of limbic thalamocortical circuits by psychomimetics and schizophrenia? Trends in Neuroscience 24, 330-334.
26. Svenningsson P, Tzavara ET, Carruthers R, Rachleff I, Wattler S, Nehls M, McKinzie DL, Fienberg AA, Nomikos GG, Greengard P (2003). Diverse psychotomimetics act through a common signaling pathway. Science 302, 1412-1415.
27. Yang J, Si T, Ling Y, Ruan Y, Han Y, Wang X, Zhang H, Kong Q, Li X, Liu C, et al. (2003). Association study of the human FZD3 locus with schizophrenia. Biological Psychiatry 54, 1298-1301.
28. Yatham LN (2003). Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disorder 5, 7-19.